Skip to main content
Publications
Cheol Lee J, Hung JY, Kim YC, Chang GC, Soo Yoo S, Yang SH, Davis KL, Nagar SP, Taylor A, Yong Lee S, Shih JY. Real-world treatment patterns in patients with EGFR mutation-positive NSCLC receiving a first line, first- or second-generation EGFR tyrosine kinase inhibitor in South Korea and Taiwan. Asian Pac J Cancer Bio. 2021 May 20;6(2). doi: 10.31557/APJCB.2021.6.2.123-132
Carrasquilla G, Porras A, Martinez S, DeAntonio R, Devadiga R, Talarico C, Caceres D, Juliao P. Pneumococcal disease mortality in children<5 years of age after pneumococcal conjugate vaccine introduction in Colombia: a time-trend analysis, 2005-2016. Poster presented at the 18th International Congress on Infectious Diseases (ICID); March 1, 2018. Buenos Aires, Argentina. [abstract] International journal of infectious diseases and therapy. 2018 Aug; 73(Supplement). doi: 10.1016/j.ijid.2018.04.3922
Strober B, Sigurgeirsson B, Popp G, Sinclair R, Krell J, Stonkus S, Septe M, Elewski BE, Gottlieb AB, Zhao Y, Herrera V, Mordin M, Odom D, Papavassilis C, Nyirady J, Lebwohl M. Secukinumab provides clearer skin and better control on patient-reported psoriasis symptoms of itching, pain, and scaling than placebo and etanercept. J Psoriasis and Psoriatic Arthritis. 2016;1(4):167-75.